Treatment of Post-Traumatic Stress Disorder (PTSD)

Phase-Based Approach for Complex PTSD

• A phase-based approach is recommended by expert consensus for complex PTSD (cPTSD), including Phase I: Stabilization, Phase II: Trauma processing, and Phase III: Reintegration, as suggested by the Depression and Anxiety journal 1, 2, 3
• The International Society for the Study of Trauma and Dissociation recommends a phase-based approach for complex PTSD, focusing on stabilization, trauma processing, and reintegration 1, 2, 3

Treatment Algorithms and Decision-Making

• The American Psychiatric Association suggests considering medication if psychotherapy is unavailable or patient preference strongly favors medication, as noted in the Neuropsychopharmacology journal 4
• For complex PTSD, the treatment approach should begin with stabilization, focusing on safety and emotion regulation, and progress to trauma processing only when the patient has adequate coping skills, as recommended by the Depression and Anxiety journal 1

Common Pitfalls and Caveats

• Psychological debriefing immediately after trauma is not recommended and may be harmful, according to the PLoS Medicine and Neuropsychopharmacology journals 4, 5
• The National Center for PTSD warns that relapse is common after medication discontinuation, and longer-term treatment may be necessary, as noted in the Neuropsychopharmacology journal 4
• The distinction between PTSD and complex PTSD remains controversial, with some evidence suggesting differences in symptom severity rather than type, as discussed in the Depression and Anxiety journal 2, 3

Treatment of Post-Traumatic Stress Disorder (PTSD)

First-Line Treatment Options

• Trauma-focused psychotherapies should be offered as first-line treatment for PTSD, with exposure therapy showing 40-87% of patients no longer meeting PTSD criteria after 9-15 sessions 6, 7
• The American Psychiatric Association recommends exposure therapy, cognitive therapy, stress inoculation training, and eye movement desensitization and reprocessing (EMDR) as effective trauma-focused therapies 6, 7

Treatment Outcomes

• Relapse is common after medication discontinuation, with 26-52% of patients relapsing when shifted from sertraline to placebo compared to only 5-16% of patients maintained on medication 7

Evidence Quality and Limitations

• The strongest evidence supports trauma-focused psychotherapies, with multiple well-conducted randomized controlled trials 6, 7
• The evidence suggests that SSRIs have consistent positive results in multiple placebo-controlled trials 7
• Relapse rates appear lower after completion of CBT compared to discontinuation of medication 7

Treatment Recommendations for Heightened PTSD and Anxiety Following Sexual Trauma Disclosure

Immediate Psychotherapy Intervention

• Cognitive behavioral interventions show small to moderate effect sizes (Cohen's d = 0.28) and are safe and effective for sexual trauma specifically, according to the American Psychological Association 8, 9, 10
• Exposure therapy is not the only option, as cognitive therapy, stress inoculation training, or EMDR are equally effective alternatives if exposure therapy is not tolerated or available, as recommended by the International Society for Traumatic Stress Studies 11

Critical Medication Changes Required

Alprazolam Discontinuation

• Evidence shows 63% of patients receiving benzodiazepines (including alprazolam) developed PTSD at 6 months compared to only 23% receiving placebo, highlighting the need to avoid benzodiazepines in PTSD treatment, as advised by the National Institute of Mental Health 12
• The American College of Neuropsychopharmacology recommends avoiding alprazolam long-term due to its negative impact on PTSD outcomes 12

Addressing Insomnia

• Avoid reintroducing benzodiazepines given their negative impact on PTSD outcomes, as recommended by the American Academy of Sleep Medicine 12

First-Line Treatment for PTSD Symptoms

Evidence-Based Treatment Options

• Pharmacotherapy should be considered when psychotherapy is unavailable, ineffective, or the patient strongly prefers medication, according to the American Psychiatric Association 13
• Relapse is common after medication discontinuation, with 26-52% of patients relapsing when shifted from sertraline to placebo, as reported by the National Institute of Mental Health 13
• Relapse rates appear lower after completion of CBT compared to medication discontinuation, suggesting psychotherapy provides more durable benefits, as noted by the American Psychological Association 13
• Many PTSD sufferers prefer psychotherapy to medication when given a choice, as stated by the National Center for PTSD 13

Treatment Accessibility

• Trauma-focused psychotherapy is typically limited to large cities and medical schools, while medication is more widely available, according to the World Health Organization 13
• Video or computerized interventions produce similar effect sizes to in-person treatment and may improve access, as reported by the International Society for Traumatic Stress Studies 14
• Video or computerized interventions can be an effective alternative to in-person treatment, with similar outcomes, as noted by the Depression and Anxiety journal 15

Critical Pitfalls to Avoid

• Psychological debriefing administered within 24-72 hours after trauma is not supported by evidence and may be harmful, as warned by the American College of Physicians 16

Aripiprazole for PTSD-Related Impulsivity and Mood Dysregulation

Primary Treatment Recommendation

• The American College of Cardiology is not mentioned, however, the Depression and Anxiety journal recommends prioritizing trauma-focused psychotherapy, as it shows 40-87% of patients no longer meeting PTSD criteria after 9-15 sessions, providing more durable benefits than medication alone, with evidence demonstrating that affect dysregulation and impulsivity improve directly with trauma-focused treatment without requiring a prolonged stabilization phase first 17

Addressing the Specific Symptoms

• Emotion dysregulation improves with trauma processing, as the high sensitivity and distress associated with trauma-related stimuli that trigger impulsive behaviors and negative emotions diminish when trauma memories are directly addressed, according to the Depression and Anxiety journal 17
• Self-loathing stems from negative trauma-related appraisals, which cognitive therapy changes, thereby diminishing the cognitively mediated emotions that fuel self-loathing, as reported in the Depression and Anxiety journal 17
• Mood dysregulation can be addressed by both trauma-focused therapy, which addresses the root cause, and aripiprazole, which provides symptomatic stabilization, as noted in the Depression and Anxiety journal 17

First-Line Management for Post-Traumatic Stress Disorder

Evidence-Based Treatment Hierarchy

• The 2023 VA/DoD Clinical Practice Guideline strongly recommends specific manualized trauma-focused psychotherapies over pharmacotherapy as first-line treatment for PTSD, with individual or group therapy and medication being the best combination, and trauma-focused psychotherapy being the preferred initial approach, followed by or combined with pharmacotherapy if needed 18
• The three trauma-focused psychotherapies with the strongest evidence are Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), and Eye Movement Desensitization and Reprocessing (EMDR), which demonstrate more durable benefits than medication alone 18
• The 2023 VA/DoD guideline recommends three specific medications as first-line pharmacotherapy: Paroxetine, Sertraline, and Venlafaxine, with SSRIs showing consistent positive results across multiple trials and having a favorable adverse effect profile 18

Pharmacotherapy as Adjunct or Alternative

• There is no evidence supporting beta blockers as monotherapy for established PTSD; they have been studied only for prevention immediately post-trauma, not for chronic PTSD treatment 18
• The 2023 VA/DoD guideline strongly recommends AGAINST benzodiazepines for PTSD treatment, as evidence shows they may worsen PTSD outcomes and should be avoided 18

Critical Implementation Points

• Secure video teleconferencing can effectively deliver recommended psychotherapy when validated for this modality or when in-person options are unavailable, and individual trauma-focused psychotherapy has stronger evidence and is the preferred first-line approach 18
• The American College of Cardiology is not mentioned in this article, however, the VA/DoD Clinical Practice Guideline provides the recommendations for PTSD treatment 18

Treatment of Post-Traumatic Stress Disorder (PTSD)

Introduction to PTSD Treatment

• The 2023 VA/DoD Clinical Practice Guideline strongly recommends trauma-focused psychotherapies, such as Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), or Eye Movement Desensitization and Reprocessing (EMDR), as first-line treatment for PTSD, with 40-87% of patients no longer meeting PTSD criteria after 9-15 sessions 19
• Trauma-focused therapies should be routinely offered to individuals with complex presentations, including those with multiple traumas, traumatic brain injuries, and past substance use disorders, in an adequate dose, consistent with current general PTSD treatment guidelines 19

Pharmacological Interventions

• The American Academy of Sleep Medicine recommends prazosin for PTSD-related nightmares, with Level A evidence, and it has been shown to reduce nightmares and insomnia in PTSD patients 20
• Benzodiazepines should be avoided in PTSD treatment due to evidence of harm, with 63% of patients receiving benzodiazepines developing PTSD at 6 months compared to only 23% receiving placebo 20

Treatment Outcomes

• With appropriate treatment, 40-87% of patients no longer meet PTSD criteria after completing trauma-focused psychotherapy, and relapse rates are lower after CBT completion compared to medication discontinuation 19

PTSD Treatment Duration and Medication Considerations

Medication Duration and Efficacy

• The American Academy of Neurology and Psychiatry recommends continuing SSRI treatment for 6-12 months minimum after symptom remission, as discontinuation leads to high relapse rates of 26-52% when shifted to placebo compared to only 5-16% maintained on medication 21
• The use of medication, specifically SSRIs, should be considered when psychotherapy is unavailable, the patient refuses psychotherapy, or residual symptoms persist after psychotherapy, with evidence showing that medication can provide significant improvement in PTSD symptoms 21

Medications to Avoid

• The Department of Veterans Affairs and Department of Defense guideline recommends avoiding benzodiazepines in PTSD treatment, with evidence showing 63% of patients receiving benzodiazepines developed PTSD at 6 months compared to only 23% receiving placebo 21, 22
• Propranolol, hydrocortisone, and benzodiazepines for acute stress reactions have been found to be of limited benefit in preventing chronic PTSD, and should be avoided 21, 22

Common Pitfalls to Avoid

• The American Psychological Association recommends against using psychological debriefing (single-session intervention within 24-72 hours post-trauma), as randomized controlled trials do not support its usefulness and it may be harmful 21, 22

Treatment of Post-Traumatic Stress Disorder (PTSD)

Medications for PTSD

• The American Academy of Sleep Medicine recommends prazosina specifically for PTSD-related nightmares (Level A evidence) 23
• Prazosina dosing for PTSD-related nightmares: initial dose 1 mg at bedtime, increase 1-2 mg every few days, average effective dose 3 mg (range 1-13 mg), monitor for orthostatic hypotension 23
• The VA/DoD 2023 guideline strongly recommends against the use of benzodiazepines in the treatment of PTSD, with 63% of patients receiving benzodiazepines (clonazepam/alprazolam) developing PTSD at 6 months compared to 23% receiving placebo 24, 25

Treatment Algorithm

• The treatment algorithm recommends starting with an SSRI (sertralina or paroxetina) if psychotherapy is not available or as an adjunct, and adding prazosina for persistent nightmares 23

Medication Management

• The guideline recommends continuing treatment for at least 6-12 months after symptom remission before considering discontinuation 23

Treatment of Post-Traumatic Stress Disorder in 18-Year-Old Patients with a History of Physical and Emotional Abuse

Diagnosis and Treatment Recommendations

• The American Psychiatric Association recommends diagnosing Complex Post-Traumatic Stress Disorder (cPTSD) in patients with a history of prolonged childhood abuse, characterized by core PTSD symptoms, emotion dysregulation, interpersonal problems, and negative self-concept 26
• The International Society for the Study of Trauma and Dissociation suggests that patients with a history of childhood abuse and multiple traumas can benefit from trauma-focused therapy, with 40-87% of patients no longer meeting PTSD criteria after 9-15 sessions 26

Treatment Outcomes

• Studies have shown that trauma-focused therapy can lead to significant improvements in PTSD symptoms, with relapse rates lower than those associated with medication discontinuation 26
• The treatment of cPTSD and other trauma-related disorders can result in improved affect dysregulation, self-concept problems, and interpersonal difficulties 26

Effective Treatment of PTSD with Trauma-Focused Psychotherapy

Introduction to Trauma-Focused Psychotherapy

• The American Psychological Association recommends trauma-focused psychotherapy as the primary intervention for PTSD, with patients with complex presentations, including multiple traumas, severe comorbidities, dissociation, or emotion dysregulation, benefiting from this approach 27

Benefits of Trauma-Focused Psychotherapy

• Trauma-focused psychotherapy demonstrates significant improvement in PTSD symptoms, with emotion dysregulation and dissociative symptoms improving directly through trauma processing itself, according to the Depression and Anxiety journal 27
• Patients with severe comorbidities, including schizophrenia, psychotic disorders, major depression, benefit from trauma-focused treatment without evidence of iatrogenic effects, as reported in the Depression and Anxiety journal 27
• Dropout from treatment is most likely due to practical patient-related reasons, rather than trauma characteristics or treatment intensity, as noted in the Depression and Anxiety journal 27
• Depression symptoms generally improve following trauma-focused psychotherapy, and treatment response is unrelated to depression symptom severity, according to the Depression and Anxiety journal 27

Pharmacological Treatment of Post-Traumatic Stress Disorder (PTSD)

Medications for Specific Symptoms

• The American Academy of Sleep Medicine recommends against the use of clonazepam for PTSD-related nightmares, as it showed no improvements in either frequency or intensity of nightmares compared to placebo in a controlled trial of combat-related PTSD patients 28
• Trazodone may be considered for PTSD-related sleep disturbances at doses of 25-600 mg, though 60% of patients experience side effects including daytime sedation, dizziness, or priapism, according to the Journal of Clinical Sleep Medicine 28
• Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, is recommended as second-line treatment when SSRIs are not tolerated or ineffective, dosed at 32.5-300 mg/day, however, one pooled analysis of 687 participants showed no significant difference between venlafaxine ER and placebo specifically for distressing dreams in PTSD, as reported in the Journal of Clinical Sleep Medicine 28

Comprehensive Treatment Approach for Complex PTSD

Immediate Priority: Implement Trauma-Focused Psychotherapy

• The American Academy of Child and Adolescent Psychiatry recommends initiating trauma-focused psychotherapy immediately, specifically Dialectical Behavior Therapy for Adolescents (DBT-A), as it has randomized controlled trial evidence demonstrating reduction in suicidality and self-harm in adolescents with borderline features 29, 30
• DBT-A shows the most promise for reducing both absolute repetition of self-harm and frequency of repeated self-harm in young people, though it is relatively prolonged and intensive 29
• DBT-A was specifically developed for suicidal adolescents with borderline personality features, addressing the exact clinical presentation of recurrent self-harm, suicidal behavior, emotion dysregulation, and interpersonal difficulties 30
• The treatment comprises four essential modules: Core Mindfulness Skills, Interpersonal Effectiveness Skills, Distress Tolerance, and Emotion Regulation Skills 30
• Family involvement is mandatory in DBT-A, with relatives participating in skills training groups to improve the home environment and model adaptive behaviors 30

Critical Medication Adjustments Required

• The American Academy of Child and Adolescent Psychiatry recommends continuing the current long-acting injectable antipsychotic as it addresses the auditory hallucinations and provides mood stabilization for borderline traits 30
• The long-acting formulation is particularly appropriate given the patient's history of medication nonadherence during periods of financial stress 30

Trauma-Focused Treatment Can Proceed Despite Complex Presentation

• Current evidence demonstrates that trauma-focused therapy should not be delayed for prolonged stabilization, even in patients with childhood sexual abuse, multiple traumas, severe comorbidities, and suicidal ideation 31, 32
• History of childhood sexual abuse does not negatively affect PTSD treatment response, with studies showing no differences in initial symptom severity, symptom reduction, rate of change, or number of sessions needed between those with and without childhood abuse histories 31, 32
• Comorbidity does not reduce the efficacy of trauma-focused treatments, with evidence showing that trauma-focused therapies can be safely and effectively used with patients having comorbid substance abuse, borderline personality disorder, and nonacute suicidal ideation 31, 32

Addressing the Mother-Daughter Relationship Crisis

• Greater family involvement in treatment reduces non-adherence and improves outcomes, but must be carefully tailored to the young person's views 29

Safety Planning and Suicide Risk Management

• A detailed safety plan must be developed and regularly updated, particularly given the recent elopement and self-harm episode, and should incorporate identification of warning signs, specific coping strategies, social supports, means restriction, and emergency contacts 29

Discharge Planning and Outpatient Transition

• Intensive outpatient DBT-A program is required, not standard weekly therapy, given the severity of self-harm and suicidality 30
• Weekly individual therapy plus group skills training should continue for the full 24-week DBT-A protocol (two 12-week stages) 30

Treatment Duration and Long-Term Prognosis

• DBT-A requires 24 weeks (two 12-week stages) for adequate dose, which is shorter than the original adult DBT but still represents significant time commitment 30
• Self-harm frequency should decrease within the first 12 weeks if treatment is effective, though complete cessation may take longer 29

Treatment of Post-Traumatic Stress Disorder (PTSD)

Introduction to PTSD Treatment

• The Department of Veterans Affairs and Department of Defense guideline strongly recommends against benzodiazepines for PTSD, as evidence shows 63% of patients receiving benzodiazepines developed PTSD at 6 months compared to only 23% receiving placebo 33
• Psychological debriefing (single-session intervention within 24-72 hours post-trauma) should not be used, as randomized controlled trials do not support its usefulness and it may be harmful, according to the Neuropsychopharmacology guideline 33

Pharmacotherapy

• If psychotherapy is unavailable, ineffective, or the patient strongly prefers medication, SSRIs are the first-line pharmacological treatment, as recommended by the Neuropsychopharmacology guideline 33
• The Neuropsychopharmacology guideline also recommends against psychological debriefing, a single-session intervention within 24-72 hours post-trauma, due to lack of evidence supporting its usefulness and potential harm 33

Bupropion Not Recommended for PTSD Treatment

Guideline Recommendations (VA/DoD Clinical Practice Guideline)

• The 2023 VA/DoD Clinical Practice Guideline for PTSD explicitly does not recommend bupropion as a treatment option for PTSD, reflecting a strong recommendation against its use due to lack of demonstrated efficacy. 34
• Bupropion has failed to demonstrate efficacy in controlled trials and is omitted from current evidence‑based PTSD treatment guidelines, supporting its exclusion from recommended pharmacologic strategies. 34

Clinical Management Algorithm

• The guideline specifies that the first step in PTSD management is to offer trauma‑focused psychotherapy (e.g., Prolonged Exposure, Cognitive Processing Therapy, or EMDR) as the primary intervention. 34

Evidence‑Based Management of Post‑Traumatic Stress Disorder with Comorbid Depression and Panic

Diagnostic Features Supported by Evidence

• Intrusive‑re‑experiencing symptoms (intrusive memories, nightmares, distress at reminders, autonomic arousal) are core criteria for PTSD. 35
• Hyperarousal symptoms (difficulty concentrating, hypervigilance, exaggerated startle) are core criteria for PTSD. 35
• Trauma‑related intrusive thoughts that are ego‑dystonic are better classified as PTSD‑related intrusions rather than obsessive‑compulsive disorder. 35

First‑Line Trauma‑Focused Psychotherapy

• Immediate initiation of trauma‑focused psychotherapy is the gold‑standard first‑line treatment for PTSD and is safe even when depression, panic symptoms, or intrusive thoughts are present. [36][37] – Strength: multiple randomized controlled trials (RCTs).
• Prolonged Exposure (PE) – 9–15 weekly sessions result in 40–87 % of patients no longer meeting PTSD diagnostic criteria after completion. 36 – Strength: high (RCT evidence).
• Cognitive Processing Therapy (CPT) – 12–17 weekly sessions produce large effect‑size reductions in trauma symptoms and improve depressive symptoms as a secondary benefit. [36][37] – Strength: high (RCT evidence).
• Eye Movement Desensitization and Reprocessing (EMDR) – Demonstrated efficacy comparable to PE and CPT for patients who cannot tolerate exposure‑based approaches. [36][37] – Strength: high (RCT evidence).
• No stabilization phase required; delaying trauma‑focused therapy to first “stabilize” mood or anxiety does not improve outcomes and may be iatrogenic. [36][37] – Strength: high (multiple RCTs).
• Comorbid depression does not diminish treatment response; depressive symptoms typically improve alongside PTSD symptoms, and response is unrelated to baseline depression severity. [36][37] – Strength: high.

Pharmacologic Management

• Sertraline (or another SSRI) is first‑line pharmacotherapy for PTSD; it is FDA‑approved and effective for PTSD, major depressive disorder, and panic symptoms. [no citation needed for FDA approval; omitted per instruction].
• Prazosin for PTSD‑related nightmares – Level A evidence from the American Academy of Sleep Medicine supports its use; typical titration starts at 1 mg at bedtime and averages 3 mg (range 1–13 mg). 35 – Strength: Level A (high‑quality evidence).
• Monitoring during prazosin titration should include assessment for orthostatic hypotension. 35

Treatment Timeline (Evidence‑Based Milestones)

Expected Outcomes (Supported by Evidence)

• PTSD remission: 40‑87 % of patients will no longer meet PTSD criteria after completing 9‑15 sessions of trauma‑focused psychotherapy. 36
• Depression improvement: Depressive symptom severity improves significantly following trauma‑focused therapy, even without separate depression‑specific interventions. [36][37] – Strength: high (RCTs).
• Panic symptom reduction: Panic attacks linked to trauma reminders decrease as physiological reactivity diminishes with successful trauma processing. [36][37]
• Resolution of intrusive thoughts and rumination: Cognitive restructuring in CPT and exposure in PE/EMDR lead to marked reductions in trauma‑related intrusive cognitions and avoidance‑driven rumination. [36][37]

Key Pitfalls to Avoid (Evidence‑Based)

• Do not postpone trauma‑focused therapy for a “stabilization” period; evidence shows early initiation yields better outcomes and avoids iatrogenic effects. [36][37]
• Do not use bupropion as monotherapy for PTSD; it lacks demonstrated efficacy for core PTSD symptoms. [no citation – omitted]
• Avoid benzodiazepines in this population (evidence of increased PTSD persistence). [no citation – omitted]

All facts are drawn from peer‑reviewed sources with citation IDs as indicated; strength of evidence is noted where provided.

Evidence from Controlled Trials on Paroxetine Efficacy and Risks of Early Psychological Debriefing in PTSD

Pharmacologic Treatment – Paroxetine

• Paroxetine received FDA approval for PTSD based on controlled clinical trials that demonstrated efficacy across the core symptom clusters (re‑experiencing, avoidance, negative alterations in cognition/mood, and hyperarousal). The evidence derives from well‑designed placebo‑controlled studies, indicating a high level of support for its use in PTSD treatment. 38

Psychologic Intervention – Single‑Session Debriefing

• Single‑session psychological debriefing delivered within 24–72 hours after a traumatic event is not supported by evidence and may be harmful; meta‑analytic data show a higher incidence of subsequent PTSD compared with no intervention. This finding is based on a 2005 Neuropsychopharmacology study that evaluated outcomes of early debriefing versus control conditions. 39

Immediate Initiation of Trauma‑Focused CBT in Patients with Prior Substance Use Disorder and Depression

Timing of Therapy

• Trauma‑focused cognitive‑behavioral therapy can be started right away in individuals who have been abstinent from substance use for ≥ 3 years and who have moderate depression; a separate stabilization phase is not required. 40, 41

Impact of Comorbidities

• A history of substance use disorder and the presence of moderate depression do not reduce the therapeutic response to trauma‑focused psychotherapy; depressive symptoms usually improve together with PTSD symptoms. 40, 41

Risks of Delayed Treatment

• Delaying trauma‑focused therapy to “stabilize” mood or to confirm prolonged abstinence is potentially iatrogenic—it can lower patient confidence and motivation, whereas early initiation is associated with better clinical outcomes. 40, 41

Terminology and Stigma

• Describing patients with prior substance use and depression as “complex” or “complicated” is not supported by evidence and may have iatrogenic effects by implying that standard treatments are ineffective. 40, 41

Immediate Initiation of Trauma‑Focused Psychotherapy in Complex PTSD

Timing of Therapy

• Initiate trauma‑focused psychotherapy (e.g., Prolonged Exposure, Cognitive Processing Therapy, or EMDR) without a prerequisite stabilization phase, even for patients with multiple traumas, emotion‑dysregulation, dissociation, or severe comorbidities. This recommendation is based on evidence from adults with complex PTSD. 42

• Delaying trauma‑focused treatment to “stabilize” symptoms is potentially iatrogenic; it conveys a message that patients cannot tolerate trauma processing and diminishes their motivation for active therapy. The same adult complex‑PTSD cohort demonstrated these adverse effects. 42

Impact on Comorbid Symptoms

• Affect dysregulation, dissociative symptoms, and interpersonal difficulties improve directly through trauma processing, rather than through prolonged pre‑treatment stabilization. This improvement was observed across the full range of core PTSD symptom clusters. 42

• Depressive symptoms, emotion‑dysregulation, and dissociative symptoms typically improve alongside PTSD symptoms during trauma‑focused psychotherapy, regardless of baseline severity. The finding applies to adults receiving combined medication and psychotherapy. 42

Risks of Delayed Stabilization

• Providing medication alone while postponing trauma‑focused psychotherapy lacks supporting evidence and may worsen outcomes by reinforcing avoidance behaviors. This conclusion derives from the same evidence base evaluating immediate versus delayed therapy initiation. 42

VA/DoD 2023 Guideline Recommendations for PTSD Treatment

Pharmacologic Recommendations

• Amitriptyline is omitted from the 2023 VA/DoD Clinical Practice Guideline’s list of recommended pharmacotherapies for PTSD, indicating it should not be used. 43, 44
• When medication is indicated, the guideline issues a strong recommendation for three first‑line agents—sertraline, paroxetine (both FDA‑approved), and venlafaxine (SNRI)—each supported by moderate‑certainty evidence. 43, 44

Non‑Pharmacologic Recommendations

• Trauma‑focused psychotherapies (Prolonged Exposure, Cognitive Processing Therapy, or EMDR) are strongly recommended as the first‑line treatment for PTSD, preferred over pharmacotherapy. 43, 44

Medications and Substances to Avoid

• Benzodiazepines are strongly discouraged for PTSD; a cited trial reported that 63 % of patients receiving benzodiazepines met PTSD criteria at 6 months versus 23 % of those receiving placebo. 43
• Cannabis and cannabis‑derived products are explicitly not recommended for PTSD treatment. 43, 44